(NASDAQ: SLNO) Soleno Therapeutics's forecast annual revenue growth rate of 96.59% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 51.65%, and it is also forecast to beat the US market's average forecast revenue growth rate of 17.18%.
Soleno Therapeutics's revenue in 2026 is $190,405,000.On average, 12 Wall Street analysts forecast SLNO's revenue for 2026 to be $24,618,636,242, with the lowest SLNO revenue forecast at $21,937,781,981, and the highest SLNO revenue forecast at $28,121,866,940. On average, 11 Wall Street analysts forecast SLNO's revenue for 2027 to be $37,019,845,766, with the lowest SLNO revenue forecast at $27,289,165,626, and the highest SLNO revenue forecast at $44,719,622,640.
In 2028, SLNO is forecast to generate $52,398,749,760 in revenue, with the lowest revenue forecast at $39,208,719,648 and the highest revenue forecast at $60,142,407,360.